Statistics issues relevant to CNS drug development

Essential CNS Drug Development

Volumn , Issue , 2012, Pages 100-126

  Mallinckrodt, Craig H ^a   Prucka, William R ^a   Molenberghs, Geert ^b,c  

^a ELI LILLY AND COMPANY   (United States)

^b HASSELT UNIVERSITY   (Belgium)

^c UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84925017129     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1017/CBO9780511977640.008     Document Type: Chapter

References (30)

1. Berry, D. A. and Stangl, D. K. (Eds.) (1996). Bayesian Biostatistics. New York: Marcel Dekker.
2. Chow, S.-C. and Chang, M. (2007). Adaptive Design Methods in Clinical Trials. Boca Raton, FL: Chapman and Hall/CRC.
3. Collins, L. M., Schafer, J. L., and Kam, C. M. (2001). A comparison of inclusive and restrictive strategies in modern missing data procedures. Psychol Methods, 6 (4), 330–51.
4. Gallo, P., Chuang-Stein, C., Dragalin, V., et al. (2006). Adaptive designs in clinical drug development – an executive summary of the PhRMA Working Group. J Biopharmaceut Stat, 16, 275–83.
5. Hurko, O. and Ryan, J. L. (2005). Translational research in central nervous system drug discovery. NeuroRx, 2, 671–82.
6. ICH guidelines; E4: Dose-response information to support drug registration; E8: General considerations for clinical trials. Accessed at http://www.ich.org/cache/compo/276–254–1.
7. Kemp, A. S., Kalali, A. H., et al. (2008). What is causing the reduced drugplacebo difference in recent schizophrenia clinical trials and what can be done about it? Schizophr Bull, doi:10.1093/schbul/sbn110.
8. Khan, A., Detke, M., Khan, S. R., and Mallinckrodt, C. (2003). Placebo response and antidepressant clinical trial outcome. J Nerv Ment Dis, 191, 211–18.
9. Khan, A., Schwartz, K., Redding, N., Kolts, R., and Brown, W. (2007). Psychiatric and Clinical Trial Completion Rates: Diagnosis analysis of the FDA SBA reports. Neuropsychopharmacology, 32, 2422–30.
10. Kola, I. and Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nat Rev Drug Discov, 3, 711–15.
11. Laird, N. M. (1994). Discussion to Diggle, P. J., Kenward, M. G. Informative dropout in longitudinal data analysis. Appl Stat, 43, 84.
12. Landin, R., DeBrota, D. J., DeVries, T. A., Potter, W. Z., and Demitrack, M. A. (2000). The impact of restrictive entry criterion during the placebo lead-in period. Biometrics, 56, 271–8.
13. Lieberman, J. A., Greenhouse, J., Hamer, R. M., et al. (2005). Comparing the effects of antidepressants: consensus guidelines for evaluating quantitative reviews of antidepressant efficacy. Neuropsychopharmacology, 30, 445–60.
14. Little, R. and Rubin, D. (1987). Statistical Analysis with Missing Data. New York: John Wiley & Sons.
15. Mallinckrodt, C. H., Meyers, A. L., Prakash, A., Faries, D. E., and Detke, M. J. (2007). Simple options for improving signal detection in antidepressant clinical trials. Psychopharmacol Bull, 40, 101–14.
16. Mallinckrodt, C. H., Lane, P. W., Schnell, D., Peng, Y., and Mancuso, J. P. (2008). Recommendations for the primary analysis of continuous endpoints in longitudinal clinical trials. Drug Inf J, 42, 305–19.
17. Mallinckrodt, C. H. and Kenward, M. G. (2009). Conceptual considerations regarding endpoints, hypotheses, and analyses for incomplete longitudinal clinical trial data. Drug Inf J, 43, 449–58.
18. Mallinckrodt, C. H., Detke, M. J., Prucka, W. R., Ruberg, S. J., and Molenberghs, G. (2010). Design archetypes for Phase II clinical trials in central nervous system disorders. Drug Inf J. Accepted.
19. Mallinckrodt, C. H., Detke, M. J., Prucka, W. R., Ruberg, S. J., and Molenberghs, G. (2010). Considerations for using positive controls in Phase II clinical trials of central nervous system disorders. Drug Inf J. Accepted.
20. Mallinckrodt, C. H., Detke, M. J., Prucka, W. R., Ruberg, S. J., and Molenberghs, G. (2010). Considerations for comparing a test drug with standard of care in Phase II clinical trials of central nervous system disorders. Drug Inf J. Accepted.
21. Molenberghs, G. and Kenward, M. G. (2007). Missing Data in Clinical Studies. Chichester: John Wiley & Sons.
22. Papakostas, G. I. and Fava, M. (2009). Does the probability of receiving placebo influence clinical trial outcome? A meta-regression of double-blind, randomized clinical trials in MDD. Eur Neuropsychopharmacol, 19, 34–40.
23. Piantadosi, S. (2005). Clinical Trials: A Methodologic Perspective. Hoboken, NJ: John Wiley & Sons.
24. Rutherford, B. R., Rose, S. A., Sneed, J. R., and Roose, S. P. (2009). Study design affects participant expectations: a survey. J Clin Psychopharmacol, 29, 179–81.
25. Siddiqui, O., Hung, H. M., and O’Neill, R. O. (2009). MMRM vs. LOCF: a comprehensive comparison based on simulation study and 25 NDA datasets. J Biopharmaceut Stat, 19 (2), 227–46.
26. Spiegelhalter, D. J., Abrams, K. R., and Myles, J. P. (2004). Bayesian Approaches to Clinical Trials and Health-Care Evaluation. New York: John Wiley & Sons.
27. Temple, R. and Ellenberg, S. S. (2000). Placebocontrolled trials and active-control trials in the evaluation of new treatments. Part 1: ethical and scientific issues. Ann Intern Med, 133 (6), 455–63.
28. Verbeke, G. and Molenberghs, G. (2000). Linear Mixed Models for Longitudinal Data. New York: Springer.
29. Walsh, B. T., Seidman, S. N., Sysko, R., and Gould, M. (2002). Placebo response in studies of major depression: variable, substantial, and growing. J Am Med Assoc, 287, 1840–7.
30. Yang, H., Cusin, C., and Fava, M. (2005). Is there a problem in antidepressant trials? Curr Top Med Chem, 5, 1077–86.